<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01574729</url>
  </required_header>
  <id_info>
    <org_study_id>rAd-p53NSCLC</org_study_id>
    <nct_id>NCT01574729</nct_id>
  </id_info>
  <brief_title>Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma</brief_title>
  <acronym>rAd-p53</acronym>
  <official_title>Phase II Study of Surgery Combined With Recombinant Adenoviral Human p53 Gene Therapy in Treatment Advanced Non-small-cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen SiBiono GeneTech Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen SiBiono GeneTech Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to investigate the efficacy and safety of surgery
      combined with rAd-p53 gene therapy in treatment of advanced Non-small-cell lung carcinoma
      (NSCLC). The study efficacy endpoints include overall survival, progress-free survival,
      quality of life, and local recurrent rate. The safety endpoint is complications and adverse
      effects.

      The study hypothesis: rAd-p53 gene therapy can prolong the overall survival and reduce the
      local recurrent rate.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 year after the treatment</time_frame>
    <description>determine the 3-years overall survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>adverse effects</measure>
    <time_frame>from starting treatment to 30 days after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>local recurrent rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Surgery plus post-surgery chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgery plus post-surgery chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery combined with rAd-p53 gene therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surgery combined with the surgery wound surface injection of rAd-p53 plus post-surgery chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surgery combined with rAd-p53 gene therapy</intervention_name>
    <description>Surgery combined with rAd-p53 gene therapy during surgery plus post-surgery chemotherapy</description>
    <arm_group_label>Surgery combined with rAd-p53 gene therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Surgery plus post-surgery chemotherapy</description>
    <arm_group_label>Surgery plus post-surgery chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  historically diagnosed advanced non-small lung cancer

          -  has surgery indication

          -  age 18 years old or greater

          -  life expectancy greater than 12 weeks

          -  ECOG: 0-2

          -  no prior chemotherapy, radiotherapy in 2 weeks

          -  Neutrophils≥1.5×10^9/L,platelet≥80×10^9/L, Hb≥≥80g/L,bilirubin≤1.5×2mg/dl, ALT and
             AST≤2×institutional upper limit of normal,Cr≤1.5×institutional upper limit of
             normal,coagulation tests(INR and PTT)within normal range

          -  subject provides signed informed consent

        Exclusion Criteria:

          -  hypersensitive to study drug

          -  with a coagulational test unnormal or a bleeding disorder

          -  infections

          -  with serious condition which can't stand a surgery

          -  pregnant or lactating

          -  principle investigator consider not suitable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qunyou Tan, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Surgery Research, Daping Hospital, Third Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qunyou Tan, M.D., Ph.D</last_name>
    <phone>13983770929</phone>
    <email>13983770929@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Surgery Research, Daping Hospital, Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>40042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qunyou Tang, M.D., Ph.D</last_name>
      <phone>13983770929</phone>
      <email>13983770929@163.com</email>
    </contact>
    <investigator>
      <last_name>qunyou tan, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2012</study_first_submitted>
  <study_first_submitted_qc>April 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2012</study_first_posted>
  <last_update_submitted>June 27, 2012</last_update_submitted>
  <last_update_submitted_qc>June 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>p53 gene therapy</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>post-surgery</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

